Loading…
Lobbying Spend
—
Filings
22
Firms Hired
1
Active Period
2021–2026
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5269
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 6197
National Defense Authorization Act for Fiscal Year 2027
2026 · third_quarter · Firm: TIBER CREEK GROUP
Issues related to medical devices at the Department of Defense; Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 8800
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 1399
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 2761
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5269
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 6197
National Defense Authorization Act for Fiscal Year 2027
2026 · second_quarter · Firm: TIBER CREEK GROUP
Issues related to medical devices at the Department of Defense; Issues related to H.R. 8800 - National Defense Authorization Act for Fiscal Year 2027.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 8800
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 1399
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 2761
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5269
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 6197
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 1399
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 2761
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 5269
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Client expense: — · Firm income: $60,000
Matched citations: H.R. 6197
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 1399
Issues related to FDA, Medicare reimbursement, cancer screening, workforce shortages and artificial intelligence; Issues related to H.R. 5269/S. 2761 - RESULTS Act; Issues related to H.R. 6197/S. 1399 - Health Tech Investment Act.
Client expense: — · Firm income: $60,000
Matched citations: S. 2761
Clarifying Remanufacturing to Protect Patient Safety Act of 2022
2022 · fourth_quarter · Firm: TIBER CREEK GROUP
H.R. 7253 - Clarifying Remanufacturing to Protect Patient Safety Act of 2022; Issues related to FDA and Medicare reimbursement, Consolidated Appropriations Act, 2023 (PL 117-328); Issues related to cancer care.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 7253
Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023
2022 · third_quarter · Firm: TIBER CREEK GROUP
H.R. 7253 - Clarifying Remanufacturing to Protect Patient Safety Act of 2022; H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act. H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 6833
Clarifying Remanufacturing to Protect Patient Safety Act of 2022
2022 · third_quarter · Firm: TIBER CREEK GROUP
H.R. 7253 - Clarifying Remanufacturing to Protect Patient Safety Act of 2022; H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act. H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 7253
Food and Drug Amendments of 2022
2022 · third_quarter · Firm: TIBER CREEK GROUP
H.R. 7253 - Clarifying Remanufacturing to Protect Patient Safety Act of 2022; H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act. H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell).
Client expense: — · Firm income: $50,000
Matched citations: H.R. 7667
H.R. 7253 - Clarifying Remanufacturing to Protect Patient Safety Act of 2022; H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act. H.R. 6833 Affordable Insulin Now Act (Continuing Resolution Shell).
Client expense: — · Firm income: $50,000
Matched citations: S. 4348
Clarifying Remanufacturing to Protect Patient Safety Act of 2022
2022 · second_quarter · Firm: TIBER CREEK GROUP
H.R. 7253 - Clarifying Remanufacturing to Protect Patient Safety Act of 2022; H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 7253
Food and Drug Amendments of 2022
2022 · second_quarter · Firm: TIBER CREEK GROUP
H.R. 7253 - Clarifying Remanufacturing to Protect Patient Safety Act of 2022; H.R. 7667 - Food and Drug Amendments of 2022; S. 4348 - FDA Safety and Landmark Advancements (FDASLA) Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R. 7667
Source: Senate LDA